quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 12, 2026

How Much Money Does Social Security Generate From Investing? Here's What's Inside the $2.5 Trillion Trust Fund.

View original at nasdaq.com
How Much Money Does Social Security Generate From Investing? Here's What's Inside the $2.5 Trillion Trust Fund. Key Points Social Security is set to deplete its trust fund within the next seven years…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Those hoping Social Security can simply invest its way out of the deficit will be sorely disappointed

    60% confidence
  • Congress will need to enact significant reforms affecting tax rates, taxable income, full retirement age, and possibly cost-of-living adjustments to protect Social Security

    60% confidence
  • The longer Congress waits to act on Social Security reform, the more severe the changes will have to be

    60% confidence
  • Social Security is set to deplete its trust fund within the next seven years, before the end of 2032

    60% confidence
  • Even a 100% allocation to equities wouldn't make up the deficit expected for Social Security

    60% confidence
  • The practical impact on Social Security's impending shortfall from investing in equities is negligible when considering conservative asset allocations and slow ramp up

    60% confidence
  • The income generated from Social Security investments has steadily declined over the last 15 years

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
How Much Money Does Social Security Generate From Investing? Here's What's Inside the $2.5 Trillion Trust Fund. — Source | Via News | pt.VIA.NEWS